Immuno-oncology

New data have resulted in updated guidelines for neoadjuvant cemiplimab.

Niraparib and abiraterone acetate (Akeega; Janssen Pharmaceutical Companies of Johnson & Johnson) is the first-and-only dual action tablet that combines a PARP inhibitor with abiraterone acetate administered with prednisone.

Precision therapies, although effective in earlier stages, may not work later.

Microgravity provides researchers with a unique environment for studying how cells behave differently than they do on Earth.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.

Pembrolizumab is already indicated to treat patients with unresectable or metastatic melanoma, along with stage 2B-3 melanoma after resection in adults and pediatric patients.

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.

Nivolumab-based combinations have shown significant survival benefits across several tumor types, including melanoma and advanced renal cell carcinoma.

Memory killer cells have been shown to respond to immunotherapy, which is normally administered as a complement to other cancer treatments.

Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.

A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.

A plethora of targeted therapies, biomarker-driven therapies, and immunotherapies are now available.

Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.

Systemic treatment options have historically been limited to traditional chemotherapy agents.

Golidocitinib (DZD4205) is the first Janus kinase 1 inhibitor to be used for this aggressive and rare form of non-Hodgkin lymphoma.

Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.

Asking patients to “give us a month of [their] life” for autologous chimeric antigen receptor therapy may reduce relapse or recurrence for 4 years or more, according to expert.

Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.

Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.

Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Identifying alterations in tumor genes has enabled medical oncologists to guide patients towards more specific therapies.

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.

Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.

Study of cell exhaustion in immunotherapy-resistant tumors could significantly improve the benefits of cancer immunotherapy for patients with treatment resistant types of cancer.